Ide-cel Leads to High Real-World Remission Rates in CNS Myeloma
In a retrospective cohort of patients with central nervous system manifestations of multiple myeloma, ide-cel CAR T-cell therapy was effective.
Related Articles
FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer
The FDA granted fast track designation to PT217 for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer.
Immediate Surgery Can Improve Long-Term Outcomes in Older Breast Cancer Patients
Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.
Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024
Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.
Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer
Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.
Olverembatinib Shows Promise as Second-Line Therapy in Chronic-Phase CML
Olverembatinib demonstrates potential as a safe, effective second-line therapy for chronic-phase CML after resistance to second-generation TKIs, according to ChiCTR2200061655 trial data.
The Addition of Asciminib and Removal of Omacetaxine Mark Notable CML NCCN Guideline Updates
Neil P. Shah, MD, PhD, highlights key recent changes to the CML NCCN guidelines and details anticipated data for 2025.
Strategies That Help Patients With Cancer Cope With Anxiety – Oncology Nurse Advisor
Strategies nurses and other healthcare professionals can use to help patients with cancer cope with anxiety in inpatient and outpatient settings.
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer
Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.
Isatuximab-Based Quadruplet Significantly Boosts PFS in Transplant-Eligible NDMM
The induction regimen of isatuximab plus RVd significantly improved progression-free survival vs RVd alone in transplant-eligible patients with newly diagnosed multiple myeloma.
CM24 Plus Nivolumab and Chemo Displays Efficacy vs Chemo Alone in Metastatic PDAC
CM24 plus nivolumab and chemotherapy demonstrated an improvement in efficacy vs chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.